Reaction
Light Chain Analysis Increased reporting signals
As of the last recalculation, Light Chain Analysis Increased appears in 1,013 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is IXAZOMIB (PRR 92.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ixazomib | 115 | 92.5 | 92.9 |
| Daratumumab | 121 | 70.5 | 70.8 |
| Carfilzomib | 84 | 66.5 | 66.6 |
| Bortezomib | 177 | 49.1 | 49.2 |
| Lenalidomide | 475 | 42.6 | 42.7 |
| Pomalidomide | 171 | 40.9 | 41.0 |
| Dexamethasone 1.5 Mg | 347 | 36.5 | 36.5 |
| Dexamethasone | 347 | 36.0 | 36.1 |
| Acyclovir | 125 | 25.5 | 25.5 |
| Telmisartan | 20 | 23.5 | 23.5 |
| Thalidomide | 39 | 22.7 | 22.7 |
| Linagliptin | 17 | 19.5 | 19.5 |
| Thiamine Hydrochloride, Riboflavin 5 Phosphate Sodium, Dexpanthenol And Niacinamide | 26 | 18.1 | 18.1 |
| Selinexor | 4 | 9.5 | 9.5 |
| Tafamidis | 4 | 7.0 | 7.0 |